Pure Global
NCT03710252

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study

A Study to Investigate HCV Response Rates in Real World Patients Traditionally Excluded From Clinical Trials: The HEARTLAND Study
American Research Corporation·Phase 4·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Drug/Device/Intervention
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
American Research Corporation
Timeline & enrollment
Phase
Phase 4
Start date
Mar 01, 2016
End date
Sep 01, 2017
Enrollment
100 participants
Primary outcome

The primary analysis will be sustained virologic response 12 weeks after the last treatment dose (SVR12) for the all treated population.

Summary

This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24
 weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03710252
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03710252 through Pure Global AI's free database. This Phase 4 trial is sponsored by American Research Corporation and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.